AU2001233918A1 - Pyridinylimidazoles - Google Patents
PyridinylimidazolesInfo
- Publication number
- AU2001233918A1 AU2001233918A1 AU2001233918A AU2001233918A AU2001233918A1 AU 2001233918 A1 AU2001233918 A1 AU 2001233918A1 AU 2001233918 A AU2001233918 A AU 2001233918A AU 2001233918 A AU2001233918 A AU 2001233918A AU 2001233918 A1 AU2001233918 A1 AU 2001233918A1
- Authority
- AU
- Australia
- Prior art keywords
- pyridinylimidazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1H-imidazol-2-yl)pyridine Chemical class data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300' height='300' x='0' y='0'> </rect>
<path class='bond-0' d='M 13.6364,109.942 L 13.6364,170.029' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-0' d='M 25.6538,118.955 L 25.6538,161.016' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 13.6364,109.942 L 34.8652,103.044' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 34.8652,103.044 L 56.0941,96.1464' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 13.6364,170.029 L 34.8652,176.927' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 34.8652,176.927 L 56.0941,183.824' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 82.4245,172.574 L 94.2629,156.28' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 94.2629,156.28 L 106.101,139.985' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 106.101,139.985 L 166.189,139.985' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 106.101,139.985 L 94.2629,123.691' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 94.2629,123.691 L 82.4245,107.397' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 92.8275,142.161 L 84.5406,130.755' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 84.5406,130.755 L 76.2537,119.349' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 166.189,139.985 L 176.585,157.992' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 176.585,157.992 L 186.981,175.999' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 179.715,139.379 L 186.993,151.984' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 186.993,151.984 L 194.27,164.589' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 166.189,139.985 L 196.233,87.9482' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 210.921,192.023 L 233.621,192.023' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 233.621,192.023 L 256.32,192.023' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 256.32,192.023 L 286.364,139.985' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 250.419,178.208 L 271.45,141.782' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 286.364,139.985 L 256.32,87.9482' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 256.32,87.9482 L 196.233,87.9482' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 247.307,99.9657 L 205.246,99.9657' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="middle" x='70.7829' y='191.602' style='font-size:20px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='64.1057' y='211.631' style='font-size:20px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>H</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='202.91' y='195.027' style='font-size:20px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='70.7829' y='94.3781' style='font-size:20px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85' height='85' x='0' y='0'> </rect>
<path class='bond-0' d='M 3.36364,30.6502 L 3.36364,47.6749' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-0' d='M 6.76859,33.2039 L 6.76859,45.1212' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 3.36364,30.6502 L 10.2297,28.4192' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 10.2297,28.4192 L 17.0958,26.1883' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 3.36364,47.6749 L 10.2297,49.9058' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 10.2297,49.9058 L 17.0958,52.1368' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 21.6167,50.0984 L 25.5894,44.6305' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 25.5894,44.6305 L 29.5621,39.1625' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 29.5621,39.1625 L 46.5868,39.1625' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 29.5621,39.1625 L 25.5894,33.6946' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 25.5894,33.6946 L 21.6167,28.2267' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 25.6156,39.5235 L 22.8347,35.696' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 22.8347,35.696 L 20.0538,31.8684' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 46.5868,39.1625 L 50.0239,45.1157' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 50.0239,45.1157 L 53.461,51.069' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 50.5667,39.246 L 52.9727,43.4133' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 52.9727,43.4133 L 55.3787,47.5805' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 46.5868,39.1625 L 55.0992,24.4187' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 57.5586,53.9064 L 64.8413,53.9064' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 64.8413,53.9064 L 72.124,53.9064' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 72.124,53.9064 L 80.6364,39.1625' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 70.4521,49.9924 L 76.4107,39.6716' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 80.6364,39.1625 L 72.124,24.4187' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 72.124,24.4187 L 55.0992,24.4187' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 69.5703,27.8236 L 57.6529,27.8236' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="middle" x='19.5552' y='53.7871' style='font-size:5px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='17.6633' y='59.462' style='font-size:5px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>H</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='56.9911' y='54.7577' style='font-size:5px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='19.5552' y='26.2405' style='font-size:5px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
</svg>
 C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 title 1
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004053A GB0004053D0 (en) | 2000-02-21 | 2000-02-21 | Compounds |
| GB0004053.5 | 2000-02-21 | ||
| GB0015902A GB0015902D0 (en) | 2000-06-28 | 2000-06-28 | Compounds |
| GB0015902.0 | 2000-06-28 | ||
| PCT/GB2001/000736 WO2001062756A1 (en) | 2000-02-21 | 2001-02-21 | Pyridinylimidazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001233918A1 true AU2001233918A1 (en) | 2001-11-15 |
| AU2001233918B2 AU2001233918B2 (en) | 2004-06-24 |
Family
ID=26243690
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3391801A Pending AU3391801A (en) | 2000-02-21 | 2001-02-21 | Pyridinylimidazoles |
| AU2001233918A Ceased AU2001233918B2 (en) | 2000-02-21 | 2001-02-21 | Pyridinylimidazoles |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3391801A Pending AU3391801A (en) | 2000-02-21 | 2001-02-21 | Pyridinylimidazoles |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030166633A1 (en) |
| EP (1) | EP1257543A1 (en) |
| JP (1) | JP2003524010A (en) |
| KR (1) | KR20020073597A (en) |
| CN (1) | CN1404478A (en) |
| AR (1) | AR029803A1 (en) |
| AU (2) | AU3391801A (en) |
| BR (1) | BR0108437A (en) |
| CA (1) | CA2401036A1 (en) |
| CO (1) | CO5271680A1 (en) |
| CZ (1) | CZ20022852A3 (en) |
| HU (1) | HU0204514A3 (en) |
| IL (1) | IL151319D0 (en) |
| MX (1) | MXPA02008082A (en) |
| NO (1) | NO20023953L (en) |
| NZ (1) | NZ520753A (en) |
| PL (1) | PL357420A1 (en) |
| WO (1) | WO2001062756A1 (en) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039198A1 (en) * | 2000-11-16 | 2004-02-26 | Bender Paul E. | Compounds |
| GB0127433D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| US20050165011A1 (en) * | 2002-05-15 | 2005-07-28 | Gellibert Francoise J. | Benzoxazine and benzoxazinone substituted triazoles |
| US20040146509A1 (en) * | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
| CA2494367A1 (en) * | 2002-07-25 | 2004-02-05 | Scios Inc. | Methods for improvement of lung function using tgf-.beta. inhibitors |
| AU2003268447B2 (en) | 2002-09-06 | 2008-07-24 | Biogen Idec Ma Inc. | Pyrazolopyridines and method of making and using the same |
| CN1694871B (en) * | 2002-09-06 | 2010-06-16 | 比奥根艾迪克Ma公司 | Imidazolopyridines and methods of making and using the same |
| PL375974A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| MXPA05002332A (en) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors. |
| BR0314302A (en) | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Pyrazole Compounds as Transforming Growth Factor (TGF) Inhibitors |
| EA200500286A1 (en) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | New isotiazole and isoxasolic compounds as an inhibitors transforming growth factor (tgf) |
| OA12928A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGF) inhibitors. |
| PA8595001A1 (en) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | New heteroaromatic compounds are condensates inhibitors transforante factor (TGF) |
| US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| BRPI0508397A (en) * | 2004-03-05 | 2007-08-07 | Taisho Pharma Co Ltd | thiazole derivative or a pharmaceutically acceptable salt thereof, alk5 inhibitor, hair follicle proliferation enhancer, and hair growth enhancer or a hair growth agent |
| CN100584842C (en) | 2004-03-05 | 2010-01-27 | 大正制药株式会社 | Thiazole derivative |
| KR100749566B1 (en) * | 2004-04-21 | 2007-08-16 | 에스케이케미칼주식회사 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 and/or ALK4 INHIBITORS |
| US20080319012A1 (en) | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| WO2006028029A1 (en) * | 2004-09-07 | 2006-03-16 | Sankyo Company, Limited | Substituted biphenyl derivative |
| KR20080040677A (en) * | 2005-06-24 | 2008-05-08 | 제네랩스 테크놀로지스, 인코포레이티드 | Heteroaryl derivatives for treating viruses |
| KR100694181B1 (en) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compound useful for inducing neuron differentiation |
| WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| TW200911237A (en) | 2007-08-03 | 2009-03-16 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| AU2009227013B2 (en) * | 2008-03-21 | 2013-01-10 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| AR083868A1 (en) | 2010-12-03 | 2013-03-27 | Lilly Co Eli | Oxazole compounds [5,4-b] pyridin-5-yl |
| TR201808033T4 (en) | 2011-07-13 | 2018-06-21 | Tiumbio Co Ltd | as ALK5 or ALK4 inhibitors and 2-pyridyl substituted imidazoles. |
| MX350442B (en) * | 2011-07-29 | 2017-09-06 | Karyopharm Therapeutics Inc | Nuclear transport modulators and uses thereof. |
| PE20141170A1 (en) | 2011-07-29 | 2014-09-16 | Karyopharm Therapeutics Inc | Nuclear transport modulators containing hydrazide and its uses |
| SG11201407268SA (en) | 2012-05-09 | 2015-01-29 | Karyopharm Therapeutics Inc | Nuclear transport modulators and uses thereof |
| US9637723B2 (en) | 2012-05-30 | 2017-05-02 | Cornell University Q | Generation of functional and durable endothelial cells from human amniotic fluid-derived cells |
| AU2013313282B2 (en) | 2012-08-01 | 2018-02-01 | Ikaika Therapeutics, Llc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) |
| CN105229144A (en) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | By combination genetic engineering and chemical engineering via forward programming produce liver cell |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| US9738624B2 (en) | 2013-06-21 | 2017-08-22 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US20170107486A1 (en) | 2014-04-21 | 2017-04-20 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| WO2015162084A1 (en) | 2014-04-22 | 2015-10-29 | Universitaet Basel | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives |
| AU2015301484B2 (en) | 2014-08-15 | 2020-02-20 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| UY36294A (en) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compounds and compositions as kinase inhibitors |
| WO2017117535A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3397633A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| WO2018132279A1 (en) * | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH561717A5 (en) * | 1971-05-10 | 1975-05-15 | Ciba Geigy Ag | |
| MX9300141A (en) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Imidazole compounds of novel, process for their preparation and pharmaceutical compositions containing it. |
| WO1995003297A1 (en) * | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| JPH09124640A (en) * | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | Pyridylimidazole compound, production thereof and fungicide for agricultural and horticultural use |
| IL133766D0 (en) * | 1997-06-30 | 2001-04-30 | Ortho Mcneil Pharm Inc | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
-
2001
- 2001-02-20 CO CO01013429A patent/CO5271680A1/en not_active Application Discontinuation
- 2001-02-20 AR ARP010100755A patent/AR029803A1/en not_active Application Discontinuation
- 2001-02-21 BR BR0108437-2A patent/BR0108437A/en not_active IP Right Cessation
- 2001-02-21 HU HU0204514A patent/HU0204514A3/en unknown
- 2001-02-21 KR KR1020027010853A patent/KR20020073597A/en not_active Application Discontinuation
- 2001-02-21 AU AU3391801A patent/AU3391801A/en active Pending
- 2001-02-21 CZ CZ20022852A patent/CZ20022852A3/en unknown
- 2001-02-21 EP EP01905954A patent/EP1257543A1/en active Pending
- 2001-02-21 NZ NZ520753A patent/NZ520753A/en unknown
- 2001-02-21 JP JP2001562538A patent/JP2003524010A/en active Pending
- 2001-02-21 AU AU2001233918A patent/AU2001233918B2/en not_active Ceased
- 2001-02-21 PL PL01357420A patent/PL357420A1/en not_active Application Discontinuation
- 2001-02-21 CA CA002401036A patent/CA2401036A1/en not_active Abandoned
- 2001-02-21 US US10/204,370 patent/US20030166633A1/en not_active Abandoned
- 2001-02-21 MX MXPA02008082A patent/MXPA02008082A/en unknown
- 2001-02-21 WO PCT/GB2001/000736 patent/WO2001062756A1/en not_active Application Discontinuation
- 2001-02-21 CN CN01805374A patent/CN1404478A/en not_active Application Discontinuation
- 2001-02-21 IL IL15131901A patent/IL151319D0/en unknown
-
2002
- 2002-08-20 NO NO20023953A patent/NO20023953L/en not_active Application Discontinuation
-
2004
- 2004-01-29 US US10/767,943 patent/US20040220230A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002363250A1 (en) | Pyrazole-amides and-sulfonamides | |
| AU2002337489A1 (en) | Inexsufflator | |
| AU2001260301A1 (en) | Novel phenyl-propargylether derivatives | |
| AU2001270017A1 (en) | Liveexception system | |
| AU2002343483A1 (en) | Hydroxypropylamines | |
| AU2002343482A1 (en) | Prolyl-4-hydroxylases | |
| AU2001248603A1 (en) | Can end | |
| AU2001260537A1 (en) | 2-aminocarbonyl-9H-purine derivatives | |
| AU2002331469A1 (en) | Non-starch-polysaccharides | |
| AU2002363368A1 (en) | Hydrazono-malonitriles | |
| AU2002313565A1 (en) | Putter-heads | |
| AU2001283005A1 (en) | Iso-truss structure | |
| AU2001271211A2 (en) | Case | |
| AU2001271211A1 (en) | Case | |
| AU2001233918A1 (en) | Pyridinylimidazoles | |
| AU6419701A (en) | Electropancreatography | |
| AUPQ605800A0 (en) | Printehead assembly | |
| AU2001282743A1 (en) | Electro-powder | |
| AU2002342918A1 (en) | 2-guanidino-4-heterocyclylquinazolines | |
| AU2002360430A1 (en) | 14-methyl-epothilones | |
| AUPQ998100A0 (en) | Application development | |
| AU2001260212A1 (en) | Composition | |
| AU2002253045A1 (en) | 6-phenylbenzonaphthyridines | |
| AU2001266345A1 (en) | Five-membered-ring compound | |
| AU2001258224A1 (en) | Wavepowermachine |